Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox Administration Regimens in MDS
NCT01326845Phase 4Terminated
- Sponsor
- Novartis
- Start
- Dec 2011
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 4, randomised, open-label trial of deferasirox in Transfusional Iron Overload (TIO) (2 arms), sponsored by Novartis. Primary endpoint: Difference in the Frequency of Overall Newly Occurring GI Adverse Events at 3 months. Started Dec 2011; status: terminated.
02
Drugs
deferasirox
03
Conditions
Transfusional Iron Overload (TIO)
Beyond the preview
Go deeper on NCT01326845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01326845.